2-[2-(4-methoxyphenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone | 446301-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[2-(4-methoxyphenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone
• 英文别名: 2-[2-(4-Methoxyphenyl)pyridin-4-yl]-1-pyridin-2-ylethanone
• CAS: 446301-92-4
• 化学式: C₁₉H₁₆N₂O₂
• 分子量: 304.348
• InChiKey: RGLDZQUBKNTRAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[2-(4-methoxyphenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone 在 一水合肼 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 2-(4-Methoxyphenyl)-4-(3-pyridin-2-yl-1H-pyrazol-4-yl)pyridine
  参考文献：
  名称：

  Discovery of 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388):  A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor

  摘要：

  Inhibitors of transforming, growth factor beta (TGF-beta) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases Such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, Compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of I mg/kg, twice a day (b.i.d.). This compound significantly reduced the expression of collagen IAI mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.

  DOI：

  10.1021/jm0509905
• 作为产物：
  描述：

  2-吡啶甲酸乙酯 、 2-(4-甲氧基苯基)-4-甲基吡啶 在 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 18.5h， 以26%的产率得到2-[2-(4-methoxyphenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone
  参考文献：
  名称：

  Discovery of 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388):  A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor

  摘要：

  Inhibitors of transforming, growth factor beta (TGF-beta) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases Such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, Compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of I mg/kg, twice a day (b.i.d.). This compound significantly reduced the expression of collagen IAI mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.

  DOI：

  10.1021/jm0509905

文献信息

• Pyrazole derivatives against tgf overexpression
  申请人：——

  公开号：US20040087623A1

  公开（公告）日：2004-05-06

  Therapeutically active pyrazole derivatives of formula (I) wherein R 1 -R 3 are as defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor &bgr; (TGF-&bgr;), and pharmaceutical compositions for use in such therapy, Formula (I) 1

  公式（I）中的治疗活性吡唑衍生物，其中R1-R3如规范中所定义，其制备过程，其在治疗中的使用，特别是在治疗或预防表现为转化生长因子&bgr;（TGF-&bgr;）过度表达的疾病中的使用，以及用于此类治疗的制药组合物，公式（I）1
• Thiazolmines and their use as tgf-beta inhibitors
  申请人：——

  公开号：US20040077687A1

  公开（公告）日：2004-04-22

  Therapeutically active thiazole derivatives of formula (I) wherein R 1 and R 2 are as defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor &bgr; (TGF-&bgr;), and pharmaceutical compositions for use in such therapy. 1

  具有治疗活性的式(I)噻唑衍生物 其中 R 1 和 R 2 如说明书中所定义，其制备工艺，其在治疗中的用途，特别是在治疗或预防以转化生长因子&bgr;（TGF-&bgr;）过度表达为特征的疾病中的用途，以及用于此类治疗的药物组合物。 1
• PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION
  申请人：SmithKline Beecham Corporation

  公开号：EP1355903B1

  公开（公告）日：2005-03-16
• Discovery of 4-{4-[3-(Pyridin-2-yl)-1<i>H</i>-pyrazol-4-yl]pyridin-2-yl}-<i>N</i>-(tetrahydro-2<i>H</i>- pyran-4-yl)benzamide (GW788388):  A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor
  作者：Françoise Gellibert、Anne-Charlotte de Gouville、James Woolven、Neil Mathews、Van-Loc Nguyen、Cécile Bertho-Ruault、Angela Patikis、Eugene T. Grygielko、Nicholas J. Laping、Stéphane Huet

  DOI：10.1021/jm0509905

  日期：2006.4.1

  Inhibitors of transforming, growth factor beta (TGF-beta) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases Such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, Compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of I mg/kg, twice a day (b.i.d.). This compound significantly reduced the expression of collagen IAI mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.